Page 15 - Read Online

Page 87 Cox et al. J Transl Genet Genom 2021;5:80-8 https://dx.doi.org/10.20517/jtgg.2021.06

Availability of data and materials
Not applicable.

Financial support and sponsorship
This work was partly supported through the Mayo Clinic K2R pipeline (SSK) the Mayo Clinic Center for
Individualized Medicine (SSK), and the Predolin Foundation (SSK).

Conflicts of interest
Cox MJ and Kenderian SS are inventors on patents in the field of CART cell therapy that are licensed to
Humanigen (through Mayo Clinic). Kenderian SS is an inventor on patents in the field of CAR
immunotherapy that are licensed to Novartis (through an agreement between Mayo Clinic, University of
Pennsylvania, and Novartis), and to Mettaforge (through Mayo Clinic). Kenderian SS receives research
funding from Kite, Gilead, Juno, Celgene, Novartis, Humanigen, MorphoSys, Tolero, Sunesis, Leahlabs, and
Lentigen. These disclosures are not directly related to the content of this manuscript.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2021.

REFERENCES
1. Siegler EL, Kenderian SS. Neurotoxicity and cytokine release syndrome after chimeric antigen receptor T cell therapy: insights into
mechanisms and novel therapies. Front Immunol 2020;11:1973. DOI PubMed PMC
2. McCune JS. Rapid advances in immunotherapy to treat cancer. Clin Pharmacol Ther 2018;103:540-4. DOI PubMed
3. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J
Med 2018;378:439-48. DOI PubMed PMC
4. Schuster SJ, Bishop MR, Tam CS, et al; JULIET Investigators. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell
lymphoma. N Engl J Med 2019;380:45-56. DOI PubMed
5. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-
type specificity. Proc Natl Acad Sci U S A 1989;86:10024-8. DOI PubMed PMC
6. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains
consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad
Sci U S A 1993;90:720-4. DOI PubMed PMC
7. Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood
2014;123:2625-35. DOI PubMed PMC
8. Park JH, Rivière I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med
2018;378:449-59. DOI PubMed PMC
9. Palumbo A, Hajek R, Delforge M, et al; MM-015 Investigators. Continuous lenalidomide treatment for newly diagnosed multiple
myeloma. N Engl J Med 2012;366:1759-69. DOI PubMed
10. Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-Cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med
2019;380:1726-37. DOI PubMed
11. Xu X, Sun Q, Liang X, et al. Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its
prevention and treatment strategies. Front Immunol 2019;10:2664. DOI PubMed PMC
12. Ma S, Li X, Wang X, et al. Current progress in CAR-T cell therapy for solid tumors. Int J Biol Sci 2019;15:2548-60. DOI PubMed
PMC
13. Beatty GL, Haas AR, Maus MV, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor
activity in solid malignancies. Cancer Immunol Res 2014;2:112-20. DOI PubMed PMC
14. Brown CE, Alizadeh D, Starr R, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med
2016;375:2561-9. DOI PubMed PMC
15. Johnson LA, Scholler J, Ohkuri T, et al. Rational development and characterization of humanized anti-EGFR variant III chimeric
antigen receptor T cells for glioblastoma. Sci Transl Med 2015;7:275ra22. DOI PubMed PMC